Lilly's Lung Cancer Drug Portrazza OK'd
This article was originally published in Scrip
The FDA on Nov. 24 gave Eli Lilly and Co. the go-ahead to market Portrazza (necitumumab injection for intravenous use, 800 mg/50 mL) in combination with gemcitabine and cisplatin in the US for patients with metastatic squamous non-small-cell lung cancer (NSCLC) – the first biologic available as a first-line therapy for the very difficult-to-treat disease, which has only a five-year survival rate.
You may also be interested in...
New products continue to drive Lilly’s revenue growth and the company expects that to remain the case even if the final Phase III trial for Alzheimer’s candidate solanezumab fails later this year.
Eli Lilly & Co.'s first quarter earnings met analyst expectations with help from recently approved products, but greater growth in future years depends on a closely-watched Phase III Alzheimer's program.
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.